BC Week In Review | Jun 8, 2018
Financial News

Sirnaomics raises $25M series C1 round

Sirnaomics Inc. (Gaithersburg, Md.) raised $25 million in an untranched series C1 round led by Yuexiu New Industrial Investment. Fellow new investors Sangel Biomedical Venture Capital, HuaKong Equity Investment and Qianhai Shenghui Investment also participated....
BC Extra | Jun 7, 2018
Financial News

Sirnaomics raises $25M series C1 round

Sirnaomics Inc. (Gaithersburg, Md.) raised $25 million in an untranched series C1 round led by Yuexiu New Industrial Investment. Fellow new investors Sangel Biomedical Venture Capital, HuaKong Equity Investment and Qianhai Shenghui Investment also participated....
BC Week In Review | Feb 16, 2017
Clinical News

Cotsiranib: Ph IIa started

Sirnaomics began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate 20, 30 and 40 μg/cm 2 /day intradermal cotsiranib twice weekly for 4 weeks in about 24 patients. Patients will receive cotsiranib on 1...
BC Extra | May 5, 2016
Financial News

RNAi play Sirnaomics raises $10M

Sirnaomics Inc. (Gaithersburg, Md.) raised $10 million in a series B round from Hong Kong-based venture firm Value Measured Investment Ltd. CMO Michael Molyneaux told BioCentury the round will allow Sirnaomics to complete Phase I...
BC Week In Review | Dec 6, 2010
Company News

Sirnaomics deal

Sirnaomics partnered with an undisclosed Chinese company to develop and commercialize STP705 in China. Sirnaomics said the deal is initially valued at about RMB30 million ($4.5 million). Under the deal, Sirnaomics will receive 32% of...
BioCentury | Mar 15, 2010
Emerging Company Profile

Two is better than one: Sidebar: Sirnaomics Inc.

Sirnaomics Inc. Gaithersburg, Md. Technology: STP705 , a nanoparticle encapsulation of two siRNAs targeting TGFB1 and COX-2 Disease focus: Dermatology Clinical status: Preclinical Founded: 2007 by Patrick Lu, David Evans, George Ji and Harry Yang University...
BioCentury | Mar 15, 2010
Emerging Company Profile

Sirnaomics: Two is better than one

Current treatments for wound healing after surgery do not adequately address reduction in scar formation, and compounds in development may not address enough of the targets involved in the process, according to Sirnaomics Inc. The...
BC Week In Review | Jan 25, 2010
Company News

Sirnaomics, University of Maryland School of Medicine deal

The university granted Sirnaomics exclusive rights to U.S. Patent Application 60/173,576 covering the use of histidine-lysine polymer (HKP) for siRNA therapeutics for wound healing and ocular diseases. The parties collaborated on the discovery of Sirnanomics'...
Items per page:
1 - 8 of 8